Journal article
Circulating cotinine concentrations and lung cancer risk in the Lung Cancer Cohort Consortium (LC3)
TL Larose, F Guida, A Fanidi, A Langhammer, K Kveem, VL Stevens, EJ Jacobs, SA Smith-Warner, E Giovannucci, D Albanes, SJ Weinstein, ND Freedman, R Prentice, M Pettinger, CA Thomson, Q Cai, J Wu, WJ Blot, AA Arslan, A Zeleniuch-Jacquotte Show all
International Journal of Epidemiology | OXFORD UNIV PRESS | Published : 2018
DOI: 10.1093/ije/dyy100
Abstract
Background: Self-reported smoking is the principal measure used to assess lung cancer risk in epidemiological studies. We evaluated if circulating cotinine—a nicotine metabolite and biomarker of recent tobacco exposure—provides additional information on lung cancer risk. Methods: The study was conducted in the Lung Cancer Cohort Consortium (LC3) involving 20 prospective cohort studies. Pre-diagnostic serum cotinine concentrations were measured in one laboratory on 5364 lung cancer cases and 5364 individually matched controls. We used conditional logistic regression to evaluate the association between circulating cotinine and lung cancer, and assessed if cotinine provided additional risk-disc..
View full abstractGrants
Awarded by National Institutes of Health
Funding Acknowledgements
This work was supported by the Research Council of Norway (grant number 267776/H10). The work undertaken by T.L.L. for this paper was conducted during a postdoctoral placement at the International Agency for Research on Cancer, within the framework of an agreement between the Research Council of Norway and the Norwegian University of Science and Technology. The Lung Cancer Cohort Consortium (LC3) was supported by the National Institutes of Health/National Cancer Institute (grant number 1U1CA155340-01) and National Health and Medical Research Council (NHMRC) (Grant ID: 1050198. Collaboration with authors from the Women's Health Study was supported by the National Institutes of Health (grant numbers CA047988, CA182913, HL043851, HL080467 and HL099355). Cancer incidence data for the Campaign Against Cancer and Stroke (CLUE I) and the Campaign Against Cancer and Heart Disease (CLUE II) cohorts were provided by the Maryland Cancer Registry, Center for Cancer Surveillance and Control, Department of Health and Mental Hygiene. The CLUE authors would like to thank the State of Maryland, the Maryland Cigarette Restitution Fund and the National Program of Cancer Registries of the Centers for Disease Control and Prevention for the funds that helped support the collection and availability of the cancer registry data. The CLUE authors would also like to thank the CLUE participants and staff at the George W. Comstock Centre for Public Health Research and Prevention. The WHI programme is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through contracts HHSN268201600018C, HHSN268201600001C, HHSN268201600002C, HHSN268201600003C, and HHSN268201600004C. The authors thank the WHI investigators and staff for their dedication, and the study participants for making the programme possible. A full listing of WHI investigators can be found at: [http://www.whi.org/researchers/Documents%20%20Write% 20a% 20Paper/WHI% 20Investigator % 20Long% 20List.pdf]. The Health Professionals Follow-up Study and Nurses' Health Study were supported by a grant from the National Institutes of Health (NIH) grants UM1CA186107, P50CA127003, P01CA87969, R01CA49449, and UM1 CA167552. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The MEC cohort acknowledges partial funding from NIH grant U01 CA164973.